Difference between revisions of "Team:UI Indonesia/safety"

Line 223: Line 223:
  
 
<div style="width:900px;border: 2px solid #6D5417;margin-top:20px;margin-bottom:20px;padding-left:20px;padding-right:20px;margin-left:20px;background-image: url('https://static.igem.org/mediawiki/2015/1/10/UI_Indonesia_opacity.png');">
 
<div style="width:900px;border: 2px solid #6D5417;margin-top:20px;margin-bottom:20px;padding-left:20px;padding-right:20px;margin-left:20px;background-image: url('https://static.igem.org/mediawiki/2015/1/10/UI_Indonesia_opacity.png');">
−
<center><h1 id="judul"><p style="font-size:22px;">PCR Protocols (BioneerAccuPower premix)</p></h1></center>
+
<center><h1 id="judul"><p style="font-size:22px;">Biosafety Assesment (FTA)</p></h1></center>
  
−
<p>1. Add template DNA and primers to AccuPower® PCR tube.
+
<p>In our project, we have a principle that safety is always come first. We do concern about how if our bacteria come out to the environment and make an infertility epidemic into people when the product is already used. In order to resolve that issue, we analyze likelihood that could happen and find the assessment for each likelihood that might appear. To make our analyze easier, we use a systematic chart based on FTA (Fault Tree Analysis) methods and we hypothises the problem that could happen based on literature review and possibility that we found when we experiment our product</p>
−
Concentration of template DNA and primer 20 µl reaction 50 µl reaction Template DNA 5 – 50 ng 10 - 100 ng Primer 5 - 10 pmole 10 - 20 pmole</p>
+
<img width="300px" src="https://static.igem.org/mediawiki/2015/7/70/UI_Indonesia_FTA.png"><br><br>
−
<img width="500px" src="https://static.igem.org/mediawiki/2015/8/8a/UI_Indonesia_safety1.png"><br><br>
+
<p>From that chart, we could see that possibility that moght happen and the assessment that we could do in order to resolve the problem. Below is the table that explain assessment that we did:</p>
−
<p>2. Add distilled water to AccuPower® PCR tubes to a total volume of 20 µl or 50 µl.</p>
+
<img width="300px" src="https://static.igem.org/mediawiki/2015/b/ba/UI_Indonesia_FTA2.png"><br><br>
−
<img width="500px" src="https://static.igem.org/mediawiki/2015/9/9a/UI_Indonesia_safety2.png"><br><br>
+
<p>From that chart, we could see that possibility that moght happen and the assessment that we could do in order to resolve the problem. Below is the table that explain assessment that we did:</p>
−
<p>3. Dissolve the lyophilized blue pellet by vortexing, and briefly spin down.</p>
+
<img width="300px" src="https://static.igem.org/mediawiki/2015/f/f5/UI_Indonesia_FTA3.png">
−
<img width="500px" src="https://static.igem.org/mediawiki/2015/0/07/UI_Indonesia_safety3.png"><br><br>
+
−
<p>4. Perform PCR of samples.</p>
+
−
<img width="500px" src="https://static.igem.org/mediawiki/2015/6/6a/UI_Indonesia_safety4.png">
+
 
</div>
 
</div>
  

Revision as of 03:20, 19 September 2015

Biosafety Assesment (FTA)

In our project, we have a principle that safety is always come first. We do concern about how if our bacteria come out to the environment and make an infertility epidemic into people when the product is already used. In order to resolve that issue, we analyze likelihood that could happen and find the assessment for each likelihood that might appear. To make our analyze easier, we use a systematic chart based on FTA (Fault Tree Analysis) methods and we hypothises the problem that could happen based on literature review and possibility that we found when we experiment our product



From that chart, we could see that possibility that moght happen and the assessment that we could do in order to resolve the problem. Below is the table that explain assessment that we did:



From that chart, we could see that possibility that moght happen and the assessment that we could do in order to resolve the problem. Below is the table that explain assessment that we did: